MedPath

A Pragmatic Approach to Lowering the Risk of Diabetes Mellitus After A Diagnosis of Gestational Diabetes Mellitus

Phase 3
Conditions
Gestational Diabetes
Interventions
Registration Number
NCT04615351
Lead Sponsor
Women and Infants Hospital of Rhode Island
Brief Summary

A Pilot of Metformin Postpartum

Detailed Description

The overall goal of this proposal is to assess metformin initiation at the time of hospital discharge for women with a history of gestational diabetes mellitus (GDM) improves maternal health at 1 year post-partum. Our central hypothesis is that diabetes mellitus (DM) prevention with metformin can be initiated days after delivery, rather than months to years after delivery, and result in a pragmatic and efficacious means of preventing DM and improving weight loss over the first year post-partum. To test this hypothesis, we will perform a open-label randomized controlled trial of metformin compared to placebo routine care initiated at the time of hospital discharge in women with a history of GDM.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
200
Inclusion Criteria
  • Gestational Diabetes
Exclusion Criteria
  • Cannot tolerate metformin

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
MetforminMetforminMetformin 500 mg to be taken twice per day for two weeks and then metformin 1000 mg PO twice daily after tolerating the lower dose
Primary Outcome Measures
NameTimeMethod
Prediabetes or Diabetes1 year postpartum

glycosylated hemoglobin (HgbA1c) at 1 year postpartum (\>/= 5.7% defined as prediabetes, \>/=6.5% defined as DM

Secondary Outcome Measures
NameTimeMethod
Prediabetes or diabetes at 15 months postpartum15 months after delivery and study initiation

HgbA1c at 15 months postpartum

Trial Locations

Locations (1)

Women & Infants Hospital

🇺🇸

Providence, Rhode Island, United States

© Copyright 2025. All Rights Reserved by MedPath